Nektar Therapeutics: Unique MOA Translates To Stellar AD Maintenance Data, Strong Buy
Source: SeekingAlpha
2026-02-18 08:16:36 ET
Nektar Therapeutics (NKTR) is a clinical-stage biopharmaceutical company focused on developing novel immunology therapies for autoimmune and chronic inflammatory diseases, founded in 1990. The company utilizes proprietary technology platforms, including PEGylation, to create drug candidates that modulate immune system imbalances. Its lead candidate is rezpegaldesleukin (REZPEG), a regulatory T cell stimulator in clinical studies for atopic dermatitis (AD), alopecia areata, and type 1 diabetes....
Read the full article on Seeking Alpha
For further details see:
Nektar Therapeutics: Unique MOA Translates To Stellar AD Maintenance Data, Strong Buy
Nektar Therapeutics
NASDAQ: NKTR
NKTR Trading
-0.7% G/L:
$71.36 Last:
424,337 Volume:
$71.92 Open:
NKTR Latest News
February 26, 2026 06:00:00 pm
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets
February 24, 2026 06:00:00 pm
Nektar Therapeutics to Participate in Two Investor Conferences in March
NKTR Stock Data
$1,025,664,653
18,620,756
0.68%
46
N/A
Biotechnology & Life Sciences
Healthcare
US
San Francisco
